Theresa Heggie Sells 70,000 Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock

Key Points

• Theresa Heggie, a director at BioCryst Pharmaceuticals, sold 70,000 shares of the company on August 13, bringing her ownership down by 51.72%.
• The company reported a 49.5% year-over-year increase in revenue, posting $163.35 million for the quarter and an EPS of $0.15, surpassing analysts' expectations.
• Equities research analysts have raised target prices for BioCryst Pharmaceuticals, with a consensus price target of $16.70 and several firms giving it a "buy" or "strong-buy" rating.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Theresa Heggie sold 70,000 shares of the company's stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the sale, the director owned 65,352 shares of the company's stock, valued at $556,145.52. The trade was a 51.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX traded up $0.0150 during midday trading on Wednesday, reaching $8.2950. 472,898 shares of the stock were exchanged, compared to its average volume of 3,809,157. The business has a 50-day simple moving average of $8.95 and a two-hundred day simple moving average of $8.79. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -46.08, a P/E/G ratio of 1.90 and a beta of 1.10. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.01 and a 12 month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million during the quarter, compared to the consensus estimate of $149.59 million. The company's revenue was up 49.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.06) earnings per share. Equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Headlands Technologies LLC bought a new position in BioCryst Pharmaceuticals during the 1st quarter worth $32,000. GF Fund Management CO. LTD. bought a new position in BioCryst Pharmaceuticals during the 4th quarter worth $33,000. GAMMA Investing LLC increased its stake in BioCryst Pharmaceuticals by 1,161.8% during the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock worth $44,000 after acquiring an additional 5,449 shares during the period. New Age Alpha Advisors LLC bought a new position in BioCryst Pharmaceuticals during the 1st quarter worth $62,000. Finally, Family Legacy Financial Solutions LLC bought a new position in BioCryst Pharmaceuticals during the 2nd quarter worth $72,000. 85.88% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BCRX has been the subject of several analyst reports. Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price for the company. Bank of America raised their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday, July 1st. JPMorgan Chase & Co. raised their target price on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Wall Street Zen upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 26th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $13.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.70.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.